A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis.

doi:10.1186/s12941-026-00864-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis.

Annals of clinical microbiology and antimicrobials - 30 May 2026

Wongjarit Kanphai, Torvorapanit Pattama, Petsong Suthidee, Sawatpanich Ajcharaporn, Sawaengdee Waritta, Dhepakson Panadda, Rotcheewaphan Suwatchareeporn, Suwanpimolkul Gompol

Abstract excerpt

BACKGROUND: Rapid molecular tests have facilitated early diagnosis and guided treatment of tuberculosis (TB) by providing faster results than the gold-standard phenotypic drug susceptibility testing (DST). Anyplex™ II MTB/MDR is an RDT available in Thailand that simultaneously detects Mycobacterium tuberculosis (MTB) complex and mutations associated with isoniazid (INH) and rifampicin (RIF) resistance, enabling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Drug Resistance, Multiple, Bacterial

Share to Isoniazid

Share to Mycobacterium tuberculosis

Share to Rifampin

Share to Thailand

Share to Tuberculosis, Multidrug-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 42218473
DOI: 10.1186/s12941-026-00864-5
PMCID: PMC13459834

Genes

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A cross-sectional study on discordances between Anyplex™ II MTB/MDR and BACTEC MGIT 960 system for assessing susceptibility for Mycobacterium tuberculosis: analysis of clinical specimens from patients with isoniazid-monoresistant, rifampicin-monoresistant, and multidrug-resistant tuberculosis.PMID 42218473Read ↗

Phenotypic discordance in rifampicin resistance detection among Mycobacterium tuberculosis isolates from China: insights from whole-genome sequencing and a structured literature review.Semantic proximity Read ↗

Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis and the correlation with patient treatment outcomesSemantic proximity Read ↗

Discordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence Country.Semantic proximity Read ↗

Discordant results between Xpert MTB/RIF assay and Bactec MGIT 960 culture system regarding the detection of rifampin-resistant Mycobacterium tuberculosis isolates in Wenzhou, China.Semantic proximity Read ↗

Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand.Semantic proximity Read ↗

Off-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance ofMycobacterium tuberculosisclinical isolates in a high-volume reference laboratorySemantic proximity Read ↗

Off-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in a high-volume reference laboratory.Semantic proximity Read ↗

Unveiling the complexity of rifampicin drug susceptibility testing in Mycobacterium tuberculosis: comparative analysis with next-generation sequencing.Semantic proximity Read ↗

Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy.Semantic proximity Read ↗

How well do routine molecular diagnostics detect rifampicin heteroresistance in Mycobacterium tuberculosis ?Semantic proximity Read ↗

Evaluation of Xpert ® MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in UgandaSemantic proximity Read ↗

Deciphering rifampicin resistance among tuberculosis patients who have trace results on Xpert MTB/RIF ultra assaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.